ACADIA Pharmaceuticals Announces FDA Priority Review of NUPLAZID™ (Pimavanserin) New Drug Application for Parkinson’s Disease Psychosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 5/27/2022

1. WDAY
2. SPY
3. COST
4. ZS
5. MRVL
6. DELL
7. GPS
8. ULTA
9. AEO
10. ADSK

Go back to ACADIA Pharmaceuticals Announces FDA Priority Review of NUPLAZID™ (Pimavanserin) New Drug Application for Parkinson’s Disease Psychosis
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) Delayed: 16.59 +0.36 (2.22%)
Previous Close $16.23    52 Week High $42.49 
Open $16.23    52 Week Low $16.64 
Day High $16.64    P/E N/A 
Day Low $15.92    EPS $-0.42 
Volume 293,711